Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002233 · ClinicalTrials.gov registry record · Phase 2
A Study of a Combination of Four Drugs in Patients With Recent HIV Infection
A Phase 2 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00002233 is a Phase 2 study that has completed, run by Glaxo Wellcome. The registered enrollment target is 30 participants.
The verdict
NCT00002233, a Phase 2 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to see if it is safe to give a combination of four anti-HIV drugs to patients recently infected with HIV who have never received anti-HIV treatment. The effects of this combination of drugs on the immune system and the level of HIV in the body are studied also. The four-drug combination includes lamivudine, abacavir, amprenavir, and indinavir.
Interventions
- DRUG Lamivudine
- DRUG Indinavir sulfate
- DRUG Abacavir sulfate
- DRUG Amprenavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002233
The ClinicalTrials.gov registry entry for NCT00002233 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Lamivudine is the first listed.
NCT00002233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002233 about?
NCT00002233 is a clinical study titled "A Study of a Combination of Four Drugs in Patients With Recent HIV Infection". The purpose of this study is to see if it is safe to give a combination of four anti-HIV drugs to patients recently infected with HIV who have never received anti-HIV treatment. The effects of this combination of drugs on the immune system and the level of HIV in the body are studied also. The four-...
What is the current status of trial NCT00002233?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants.
What interventions are being tested in trial NCT00002233?
The interventions under investigation include: Lamivudine (DRUG), Indinavir sulfate (DRUG), Abacavir sulfate (DRUG), Amprenavir (DRUG).
Who is sponsoring clinical trial NCT00002233?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.